Could a common asthma drug shield newborns from kidney damage?
NCT ID NCT05853601
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether the drug theophylline can prevent kidney injury in newborns who experienced oxygen deprivation at birth (HIE) and are receiving cooling therapy. Thirty infants will receive one or two doses of theophylline within 18 hours of birth. The main goal is to see if a larger trial is possible, not yet to prove the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
theophylline (a drug similar to caffeine, given intravenously)
What this could lead to
If this works, it could point toward a way to prevent kidney injury in thousands of at-risk newborns with HIE.
What could go wrong
This is a very early, small pilot study with only 30 infants. It is designed mainly to test feasibility and safety, not to prove the drug works. Theophylline can cause side effects like rapid heart rate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States